Methods and compositions for treating hepatitis C virus

Details Methods and compositions for treating hepatitis C virus Methods and compositions for treating hepatitis C virus

2005-07-05

2005-07-05

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S025000, C514S050000, C514S04400A, C536S028100, C536S028200, C536S027100

Reexamination Certificate

active

06914054

ABSTRACT:
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

REFERENCES:
patent: 3480613 (1969-11-01), Walton et al.
patent: 5977061 (1999-11-01), Holy et al.
patent: 6340690 (2002-01-01), Bachand et al.
patent: 6348587 (2002-02-01), Schinazi et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6444652 (2002-09-01), Gosselin et al.
patent: 6573248 (2003-06-01), Ramasamy et al.
patent: 2002/0055483 (2002-05-01), Watanabe et al.
patent: 2002/0147160 (2002-10-01), Bhat et al.
patent: 2003/0008841 (2003-01-01), Devos et al.
patent: 2003/0028013 (2003-02-01), Wang et al.
patent: 2003/0060400 (2003-03-01), LaColla et al.
patent: 2003/0083307 (2003-05-01), Devos et al.
patent: 2003/0087873 (2003-05-01), Stuyver et al.
patent: 1.581.628 (1969-09-01), None
patent: 1 163 103 (1969-09-01), None
patent: 1 209 654 (1970-10-01), None
patent: 63-215694 (1988-09-01), None
patent: 06-228186 (1994-08-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 99/43691 (1999-02-01), None
patent: WO 00/09531 (2000-02-01), None
patent: WO 01/32153 (2000-11-01), None
patent: WO 01/79246 (2001-04-01), None
patent: WO 01/91737 (2001-05-01), None
patent: WO 01/92282 (2001-05-01), None
patent: WO 01/60315 (2001-08-01), None
patent: WO 01/68663 (2001-09-01), None
patent: WO 01/90121 (2001-11-01), None
patent: WO 01/96353 (2001-12-01), None
patent: WO 02/48165 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/32920 (2002-04-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/070533 (2002-09-01), None
patent: WO 02/094289 (2002-11-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 03/26589 (2003-04-01), None
patent: WO 03/026675 (2003-04-01), None
patent: WO 03/051899 A1 (2003-06-01), None
patent: WO 03/061385 (2003-07-01), None
patent: WO 03/061576 (2003-07-01), None
patent: WO 03/062255 (2003-07-01), None
patent: WO 03/062256 (2003-07-01), None
patent: WO 03/062257 (2003-07-01), None
patent: WO 03/063771 (2003-08-01), None
patent: WO 03/068162 (2003-08-01), None
patent: WO 03/072757 (2003-09-01), None
patent: WO 03/093290 (2003-11-01), None
Harry-O'Kuru, et al., “A short, flexible route toward 2′-C-branched ribonucleosides”,J. Org. Chem. 1997, 62, 1754-1759.
Carroll, Steven S. et al. “Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs”The Journal of Biological Chemistry, 2003, 278 (14), 11979-11984.
Harry-O'Kuru, Rogers E. et al. “2′-C-Alkylribonucleosides: Design, Synthesis, and Conformation”Nucleosides&Nucleotides, 1997, 16 (7-9), 1457-1460.
Matsuda et al. “Alkyl addition reaction of pyrimidine 2′-ketonucleosides: synthesis of 2′-branched-chain sugar pyrimidine nucleosides (nucleosides and nucleotides. LXXXI.)”Chemical&Pharmaceutical Bulletin, Mar. 1988, 36, 945-953.
Altmann et al,Synlett, Thieme Verlag, Stuttgart, De, 1994, 10, 853.
Altmann et al,Biorganic&Medicinal Chemistry Letters, 1994, 4, No.16, 1969.
Beigelman et al.,Nucleic Acids Symp. Ser., 1981, 9, 115.
Beigelman et al,Carbohydrate Research, 1988, 181, 77.
Berenguer et al,Proceedings of the Association of American Physicians, 1998, 110, No. 2, 98.
Czernecki et al,J. Org. Chem., 1992, 57, 7325.
Faivre-Buet et al,Nucleosides&Nucleotides, 1992, 11, No. 7, 1411.
Farkas et al,Collection Czechoslov. Chem. Comm., 1967, 32, 2663.
Federov et al,J. Med. Chem., 1992, 35, 4567.
Franchetti et al,J. Med. Chem., 1998, 41, 1708.
Grouiller et al,Synlett, 1993, 221.
Haraguchi et al,Tetrahedron Letters, 1991, 32, No. 28, 3391.
Haraguchi et al,Nucleosides&Nucleotides, 1995, 14, 417.
Hattori et al,J. Med. Chem., 1998, 41, 2892.
Iino et al,Nucleosides and Nucleotides, 1996, 15, 169.
Itoh et al,J. Org. Chem., 1995, 60, 656.
Johnson et al,Nucleosides&Nucleotides, 1995, 14, 185.
Lavaire et al,Nucleosides&Nucleotides, 1998, 17, 2267.
Kawana et al,Nucleic Acids Symp. Ser., 1986, 17, 37.
Matsuda et al,Chem. Pharm. Bull., 1987, 35, 3967.
Matsuda et al,Chem. Pharm. Bull., 1988, 36, 945.
Matsuda et al,J. Med. Chem., 1991, 34, 234.
Matsuda et al,Nucleosides&Nucleotides, 1992, 11, No. 2/4, 197.
Mikhailov et al,Carbohydrate Research, 1983, 124, 75.
Mikhailov et al,Nucleosides&Nucleotides, 1991, 10, 339.
Mikhailov et al,J. Org. Chem., 1992, 57, 4122.
Ong et al,Biochemistry, 1992, 31, 11210.
Rogers et al.,Nucleosides&Nucleotides, 1997, 16, 1457.
Rosenthal et al,Carbohydrate Research, 1980, 79, 235.
Samano et al,J. Am. Chem. Soc., 1992, 114, 4007.
Samano et al,Can. J. Chem., 1993, 71, 186.
Serafinowski et al,Tetrahedron, Elsevier Science Publishers, 1999, 56, No. 2, 333.
Sharma et al,Nucleosides, Nucleotides and Nucleic acids, 2000, 19, No. 4, 757.
Tritsch et al,Bioorganic&Medicinal Chemistry Letters, 2000, 10, 139.
Tunitskaya et al,Febs Letters, 1997, 400, 263.
Usui, et al,Chem. Pharm. Bull., 1986, 34, 15.
Walczak et al,Acta Chemica Scand., 1991, 45, 930.
Walton et al,J. Med. Chem., 1969, 12, 306.
Wolfe et al,Tetrahedron Letters, 1995, 36, No. 42, 7611.
Wu et al,Tetrahedron, 1990, 46, 2587.
Francesco et al.,Antiviral Research, 58 (2003) 1-16.

Affiliated with

Also associated with

Rating

Methods and compositions for treating hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treating hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating hepatitis C virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3420631